Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate MDxHealth SA before investing.

In this article, we go over a few key elements for understanding MDxHealth SA’s stock price such as:

• MDxHealth SA’s current stock price and volume
• Why MDxHealth SA’s stock price changed recently
• Upgrades and downgrades for MDXH from analysts
• MDXH’s stock price momentum as measured by its relative strength

About MDxHealth SA (MDXH)

Before we jump into MDxHealth SA’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company’s testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Want to learn more about MDxHealth SA’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about MDxHealth SA.

MDxHealth SA’s Stock Price as of Market Close

As of September 03, 2026, 4:00 PM, CST, MDxHealth SA’s stock price was $0.726.

MDxHealth SA is up 2.28% from its previous closing price of $0.710.

During the last market session, MDxHealth SA’s stock traded between $0.703 and $0.730. Currently, there are approximately 52.52 million shares outstanding for MDxHealth SA.

MDxHealth SA’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

MDxHealth SA Stock Price History

MDxHealth SA’s (MDXH) price is currently up 0.83% so far this month.

During the month of September, MDxHealth SA’s stock price has reached a high of $0.750 and a low of $0.691.

Over the last year, MDxHealth SA has hit prices as high as $5.330 and as low as $0.400. Year to date, MDxHealth SA’s stock is down 79.66%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused MDxHealth SA Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 02, 2026, there were analysts who downgraded MDxHealth SA’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate MDxHealth SA’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on MDxHealth SA’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about MDxHealth SA (MDXH) by visiting AAII Stock Evaluator.

Relative Price Strength of MDxHealth SA

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 02, 2026, MDxHealth SA has a weighted four-quarter relative price strength of -12.50%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how MDxHealth SA is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

MDxHealth SA Stock Price: Bottom Line

As of September 3, 2026, MDxHealth SA’s stock price is $0.726, which is up 2.28% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like MDxHealth SA stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.